Portfolio company
Cage Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops drugs targeting tumor metabolism and glycolysis to treat cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Dracen Pharmaceuticals
This biotech company develops glutamine antagonist drugs to treat lung cancer and solid tumours for patients with specific genetic mutations.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.
Convert Pharmaceuticals
The company develops hypoxia-activated prodrugs that transform into anti-cancer agents to treat patients with solid tumours.
Calithera BioSciences
This biopharmaceutical company develops small-molecule drugs targeting tumor metabolism and immunology to treat patients with various forms of cancer.
OnCusp Therapeutics
This biopharmaceutical company develops oncology therapies by advancing preclinical drug candidates through clinical trials for cancer patients and potential pharmaceutical partners.
Calithera
This pharmaceutical company develops small-molecule drugs targeting cancer metabolism and tumour immunology for healthcare providers and patients with oncology and haematology conditions.
Signase
This biotechnology company develops small molecule inhibitors of cell replication pathways to treat cancer patients by inhibiting tumour growth.
D2G Oncology
This company develops genomic drug screening platforms and mouse models to identify genotype-specific cancer treatments for healthcare institutions and pharmaceutical researchers.